Chūō-ku, Japan
Chūō-ku, Japan

Time filter

Source Type

Patent
Anaeropharma Science Inc. | Date: 2017-03-15

An object is to provide a signal peptide that can secrete a heterogeneous polypeptide with high efficiency outside the bacterial cell in a bacterium of the genus Bifidobacterium, an expression cassette that can secrete a heterogeneous polypeptide with high efficiency outside the bacterial cell, a heterogeneous polypeptide expression vector, a bacterium of the genus Bifidobacterium capable of secreting a heterogeneous polypeptide. Means for attaining the object is a bacterium of the genus Bifidobacterium transformed by a vector having an expression cassette sequentially comprising a promoter DNA functioning in a bacterium of the genus Bifidobacterium, a DNA encoding the secretory signal peptide, a DNA encoding a scFv antibody having an antitumor activity, and a terminator DNA functioning in the bacterium of the genus Bifidobacterium; and capable of secreting the scFv antibody with high efficiency outside the bacterial cell.


Patent
Anaeropharma Science Inc. | Date: 2013-01-24

A conventional shuttle vector constructed by fusing an E. coli-derived plasmid and a transformant-derived plasmid functions in both E. coli and the transformant bacterium, and there exists no expression vector that functions only in a non-E. coli transformant. The present invention provides an plasmid expression vector comprising (1) a plasmid replication unit that functions in an anaerobic microorganism other than E. coli and (2) a protein expression unit formed from DNA coding for a protein having target activity and a DNA fragment containing a promoter and a terminator that function in the anaerobic microorganism. The expression vector of the present invention is capable of being replicated only in a transformant, eliminating the risk of the replication of the transformant gene in other pathogenic or aerobic bacterium, providing an extremely safe and reliable vector and gene transporter for therapeutic application.


Patent
Anaeropharma Science Inc. | Date: 2012-07-13

[Object] To provide a gene transfer carrier that specifically accumulates only at a disease site even with systemic administration, has a high protein expression rate, and disappears from the disease site accompanying a cure, and a method for the treatment of an ischemic disease using same. [Solution means] The above-mentioned object has been accomplished by providing a gene transfer carrier formed from an anaerobic bacterium that can grow specifically at the site of an ischemic disease and can express at least one type of protein that is useful for the diagnosis or treatment of an ischemic disease, a pharmaceutical composition containing the gene transfer carrier, and a treatment method for an ischemic disease utilizing same.


Patent
Anaeropharma Science Inc. | Date: 2015-04-20

To provide a gene transfer carrier that specifically accumulates only at a disease site even with systemic administration, has a high protein expression rate, and disappears from the disease site accompanying a cure, and a method for the treatment of an ischemic disease using same. The above-mentioned object has been accomplished by providing a gene transfer carrier formed from an anaerobic bacterium that can grow specifically at the site of an ischemic disease and can express at least one type of protein that is useful for the diagnosis or treatment of an ischemic disease, a pharmaceutical composition containing the gene transfer carrier, and a treatment method for an ischemic disease utilizing same.


Provided are: an obligatory anaerobic lactic acid bacterium expected as being usable as a safe remedy for a disease under an anaerobic environment, such as solid tumor, and a gene transport support, which is no danger of exerting side effects in a normal tissue; a method for constructing the same; and an expression vector which is useful in the construction method. The aforesaid obligatory anaerobic lactic acid bacterium is characterized by having been artificially mutated from a facultative anaerobe into an obligatory anaerobe, and being further transformable by an expression vector carrying a gene, which expresses an active protein useful in treating a disease under an anaerobic environment, transferred thereinto. The aforesaid expression vector is characterized by being an expression vector capable of functioning in an obligatory anaerobic lactic acid bacterium, which contains a plasmid replication protein gene(Rep)originating in a lactobacillus, a secretion signal sequence (PslpA-SSartP) consisting of an s-layer gene promoter originating in a lactobacillus and a PrtP protein secretion signal originating in a lactobacillus, and one or more kinds selection marker genes. Thus, it is possible to provide a remedy for a disease under an anaerobic environment and a microbial gene transport support which are highly safe and excellent.


Patent
Anaeropharma Science Inc. | Date: 2012-06-27

An object of the present invention is to provide a method of efficiently constructing a gene delivery carrier having a favorable activity and expression efficiency of a protein expressed by a gene introduced by transformation. Moreover, an object of the present invention is to provide a pharmaceutical composition comprising a gene delivery carrier constructed by the construction method and a therapeutic agent for solid tumor comprising the resistant bacterium. The objects of the present invention have been attained by a gene delivery carrier consisting of an anaerobic microorganism capable of growing in a tumor tissue in an anaerobic environment and capable of expressing (A) a protein having an antitumor activity or (B) a protein having an activity of converting an antitumor substance precursor to an antitumor substance, wherein DNA encoding the protein of interest is allowed to further comprise, on the 5-terminal side thereof, a DNA fragment comprising a nucleotide sequence encoding a peptide consisting of an amino acid sequence from the 1st to at least 4th amino acids at the N-terminus of a histone-like DNA-binding protein.


Patent
Anaeropharma Science Inc. | Date: 2012-12-05

The present invention relates to a novel secretory signal, a novel plasmid containing the secretory signal, a transformed anaerobic bacterium transformed with said plasmid, a gene transfer carrier consisting of said anaerobic bacterium, and a pharmaceutical composition containing said carrier.


Patent
Anaeropharma Science Inc. | Date: 2015-07-22

The present invention relates to a novel secretory signal, a novel plasmid containing the secretory signal, a transformed anaerobic bacterium transformed with said plasmid, a gene transfer carrier consisting of said anaerobic bacterium, and a pharmaceutical composition containing said carrier.


Patent
Anaeropharma Science Inc. | Date: 2014-05-21

[Object] The purpose of the present invention is to provide: a gene delivery carrier that specifically accumulates only in a lesion site even when systemically administered, has a high rate of protein expression, and disappears from the lesion site as healing occurs; and a therapeutic method for ischemic diseases using same. Said purpose is achieved by providing: a gene delivery carrier comprising an anaerobic bacteria, capable of growing specifically at an ischemic disease site, and capable of expressing at least one protein useful in the diagnosis or treatment of ischemic disease; a medical composition including said gene delivery carrier; and a therapeutic method for ischemic diseases using same.


Patent
Anaeropharma Science Inc. | Date: 2015-08-26

The present invention relates to a novel secretory signal, a novel plasmid containing the secretory signal, a transformed anaerobic bacterium transformed with said plasmid, a gene transfer carrier consisting of said anaerobic bacterium, and a pharmaceutical composition containing said carrier.

Loading Anaeropharma Science Inc. collaborators
Loading Anaeropharma Science Inc. collaborators